No Alzheimer's benefits in supplements - NIH panel
This article was originally published in The Tan Sheet
Data do not support the association of dietary supplement intake and drug regimens with reduced risk of Alzheimer's disease, says a National Institutes of Health panel. Following a state-of-the-science conference April 26-28 in Bethesda, Md., the panel said in a 1statement that longer chain omega-3 fatty acids demonstrate some reduced risk of cognitive decline in longitudinal studies and "may provide new insight into the prevention or delay of cognitive decline or Alzheimer's." Other nutritional interventions, including folate, beta-carotene and vitamins B, E and C, show no consistent cognitive benefits, the panel said. Products touting support for brain and memory health products are a growing supplement segment (2"The Tan Sheet" Dec. 21, 2009)
You may also be interested in...
Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.